MENU
+Compare
CANC
ETF ticker: NASDAQ
AS OF
Dec 24 closing price
Price
$35.63
Change
+$0.18 (+0.51%)
Net Assets
115.88M

CANC stock forecast, quote, news & analysis

The investment seeks to provide long-term growth... Show more

Category: #Health
CANC
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the ETF lost 0.00% with an average daily volume of 0 shares traded.The ETF tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for CANC with price predictions
Dec 24, 2025

Aroon Indicator for CANC shows an upward move is likely

CANC's Aroon Indicator triggered a bullish signal on December 09, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 109 similar instances where the Aroon Indicator showed a similar pattern. In of the 109 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on December 22, 2025. You may want to consider a long position or call options on CANC as a result. In of 36 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CANC advanced for three days, in of 151 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for CANC moved out of overbought territory on December 02, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 11 similar instances where the indicator moved out of overbought territory. In of the 11 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Moving Average Convergence Divergence Histogram (MACD) for CANC turned negative on December 03, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 20 similar instances when the indicator turned negative. In of the 20 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CANC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Bristol-Myers Squibb Co (NYSE:BMY), Regeneron Pharmaceuticals (NASDAQ:REGN), Illumina (NASDAQ:ILMN), Incyte Corp (NASDAQ:INCY).

Industry description

The investment seeks to provide long-term growth. Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.

Market Cap

The average market capitalization across the Tema Oncology ETF ETF is 54.74B. The market cap for tickers in the group ranges from 3.51M to 963.92B. LLY holds the highest valuation in this group at 963.92B. The lowest valued company is NOVN at 3.51M.

High and low price notable news

The average weekly price growth across all stocks in the Tema Oncology ETF ETF was 4%. For the same ETF, the average monthly price growth was 2%, and the average quarterly price growth was 42%. MREO experienced the highest price growth at 20%, while ARGX experienced the biggest fall at -1%.

Volume

The average weekly volume growth across all stocks in the Tema Oncology ETF ETF was -59%. For the same stocks of the ETF, the average monthly volume growth was -75% and the average quarterly volume growth was -82%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 72
Price Growth Rating: 46
SMR Rating: 79
Profit Risk Rating: 75
Seasonality Score: 1 (-100 ... +100)
View a ticker or compare two or three
CANC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
United Satets
Phone
N/A
Web
www.tema.co